Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Zymeworks Inc. (ZYME)

Zymeworks raises 2026 revenue guidance to $337M-$351M after $250M Jazz milestone

Positive Impact 4 of 5 earnings

Zymeworks reported third quarter 2026 net income of $173.7 million, compared with a net loss of $19.6 million a year earlier, driven mainly by a $250 million milestone from Jazz Pharmaceuticals after the U.S. approval of Ziihera for first-line HER2-positive gastroesophageal adenocarcinoma. The company raised its 2026 total revenue guidance to $337 million to $351 million from $278 million to $292 million. Higher selling, general and administrative costs tied to the Theravance Biopharma acquisition partly offset the gain.

Key points

  • Q3 2026 total revenue was $256.5 million, compared with $27.6 million in Q3 2025.
  • Q3 2026 diluted earnings per share were $2.28, compared with a loss of $0.26 per share in Q3 2025.
  • 2026 adjusted EBITDA guidance was raised to $176 million to $190 million from $114 million to $128 million.
  • SG&A expenses rose to $42.7 million from $14.1 million, mainly due to Theravance Biopharma acquisition costs, which closed September 23, 2026.

The filing

CompanyZymeworks Inc. (ZYME)
Form8-K, current report
Filed with the SECNov 9, 2026, 4:08 PM ET
Accession number0001937653-26-000067

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 6:16 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.